Najaf Zare1, Saeed Ghanbari, Alireza Salehi. 1. Department of Biostatistics, Research Center of Infertility, Shiraz University of Medical Sciences, Shiraz, Iran. najafzare@sums.ac.ir
Abstract
BACKGROUND: To compare the effects of two adjuvant chemotherapy regimens, anthracycline-based and cyclophosphamide, methotrexate, fluorourical (CMF) on disease free survival for breast cancer patients in the Eastern Mediterranean region and Asia. METHODS: In a systematic review with a multivariate mixed model meta-analysis, the reported survival proportion at multiple time points in different studies were combined. Our data sources were studies linking the two chemotherapy regimens on an adjuvant basis with disease free survival published in English and Persian in the Eastern Mediterranean region and Asia. All survival curves were generated with Graphdigitizer software. RESULTS: 14 retrospective cohort studies were located from electronic databases. We analyzed data for 1,086 patients who received anthracycline-based treatment and 1,109 given CMF treatment. For determination of survival proportions and time we usesb the transformation Ln (-Ln(S)) and Ln (time) to make precise estimations and then fit the model. All analyses were carried out with STATA software. CONCLUSIONS: Our findings showed a significant efficacy of anthracycline-based adjuvant therapy regarding disease free survival of breast cancer. As a limitation in this meta-analysis we used studies with different types of anthracycline-based regimens.
BACKGROUND: To compare the effects of two adjuvant chemotherapy regimens, anthracycline-based and cyclophosphamide, methotrexate, fluorourical (CMF) on disease free survival for breast cancerpatients in the Eastern Mediterranean region and Asia. METHODS: In a systematic review with a multivariate mixed model meta-analysis, the reported survival proportion at multiple time points in different studies were combined. Our data sources were studies linking the two chemotherapy regimens on an adjuvant basis with disease free survival published in English and Persian in the Eastern Mediterranean region and Asia. All survival curves were generated with Graphdigitizer software. RESULTS: 14 retrospective cohort studies were located from electronic databases. We analyzed data for 1,086 patients who received anthracycline-based treatment and 1,109 given CMF treatment. For determination of survival proportions and time we usesb the transformation Ln (-Ln(S)) and Ln (time) to make precise estimations and then fit the model. All analyses were carried out with STATA software. CONCLUSIONS: Our findings showed a significant efficacy of anthracycline-based adjuvant therapy regarding disease free survival of breast cancer. As a limitation in this meta-analysis we used studies with different types of anthracycline-based regimens.
Authors: Kyuwan Lee; Irene Kang; Wendy J Mack; Joanne Mortimer; Fred Sattler; George Salem; Janice Lu; Christina M Dieli-Conwright Journal: Breast Cancer Res Treat Date: 2019-06-24 Impact factor: 4.872
Authors: Kyuwan Lee; Irene Kang; Wendy J Mack; Joanne Mortimer; Fred Sattler; George Salem; Christina M Dieli-Conwright Journal: BMC Cancer Date: 2019-07-03 Impact factor: 4.430
Authors: Tyler J W Robinson; Melody Pai; Jeff C Liu; Frederick Vizeacoumar; Thomas Sun; Sean E Egan; Alessandro Datti; Jing Huang; Eldad Zacksenhaus Journal: Cell Cycle Date: 2013-08-12 Impact factor: 4.534
Authors: Kyuwan Lee; Irene Kang; Joanne E Mortimer; Fred Sattler; Wendy J Mack; Lindsey Avery Fitzsimons; George Salem; Christina M Dieli-Conwright Journal: BMJ Open Date: 2018-06-30 Impact factor: 2.692